



ASX ANNOUNCEMENT

12 September 2023

## Convertible Note Facility Update

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) is pleased to announce an update on the convertible note facility (**Note Facility**) that the Company has established, pursuant to which the Company is offering up to \$4.1 million of convertible notes (**Notes**), together with free-attaching options to purchase ordinary shares (**Convertible Note Options**), for issue and sale solely to Australian investors.

THE NOTES AND THE ORDINARY SHARES THAT MAY BE ISSUED UPON THE CONVERSION THEREOF, AS WELL AS THE CONVERTIBLE NOTE OPTIONS AND THE ORDINARY SHARES THAT MAY BE ISSUED UPON THE EXERCISE THEREOF, HAVE NOT BEEN, AND WILL NOT BE, REGISTERED OR QUALIFIED UNDER THE U.S. SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND, ACCORDINGLY, SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO REGISTRATION OR QUALIFICATION UNDER THE U.S. SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES LAW OR IN ACCORDANCE WITH AN AVAILABLE EXEMPTION THEREFROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION OR QUALIFICATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES LAWS.

The Company is pleased to note that it has issued 3,620,000 Notes, together with 4,990,000 Convertible Note Options, under the Note Facility, increasing the total amount raised to date to \$3.62 million.

The Note Facility and the offering contemplated thereby was approved by the Company's shareholders at the Extraordinary General Meeting held on 28 August 2023. The key terms of the Note Facility are described in the Notice of Extraordinary General Meeting dated 26 July 2023.

**Approved by the Board of Directors and Released by the Company Secretary**

- ENDS -

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe  
rod.hinchcliffe@mcpartners.com.au

**Media Relations**

Melissa Hamilton  
melissa.hamilton@mcpartners.com.au



## **Investor Relations – USA**

Matt Selinger

Managing Director, Integrous Communications

[mselinger@integcom.com](mailto:mselinger@integcom.com)

### **About CardieX**

CardieX is a medical technology company focused on developing vascular biomarkers. Its ATCOR subsidiary is a leader in medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's SphygmoCor® central blood pressure technology. CardieX's CONNEQT subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

### **Forward Looking Statements**

This announcement contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Forward looking statements should, or can generally, be identified by the use of forward-looking words such as "believe", "expect", "estimate", "will", "may", "target" and other similar expressions within the meaning of securities laws of applicable jurisdictions, and include but are not limited to the expected outcome of the acquisition. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors are not all within the control of CardieX and cannot be predicted by CardieX and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which CardieX operates. They also include general economic conditions, exchange rates, interest rates, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised.

None of CardieX or any of its subsidiaries, advisors or affiliates (or any of their respective officers, employees or agents) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward-looking statement or any outcomes expressed or implied in any forward-looking statements. Statements about past performance are not necessarily indicative of future performance.